Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Press Releases
Read more
Recent/Upcoming Events
May 16, 2024 at 1:30 PM EDT
GLP-1-Based Therapeutics Summit

Title: Attaining Product Differentiation through Improved Patient Segmentation & Efficiency

Speaker: Dr. Scott Harris, Chief Medical Officer, Altimmune

May 15, 2024 at 10:00 AM EDT
GLP-1-Based Therapeutics Summit

Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease

Speaker: Dr. Scott Harris, Chief Medical Officer, Altimmune

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe